6 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $61M | -$11M | 65.8% | -13.3% | — | $25M | $24M |
| 2024 | $55M | -$15M | 62.1% | -24.8% | -$24M | $25M | $20M |
| 2023 | $60M | -$4M | 61.6% | -3.5% | $240000 | $15M | $27M |
| 2022 | $71M | -$30M | 56.7% | -38.8% | -$34M | $28M | $32M |
| 2021 | $63M | -$44M | 49.2% | -55.2% | — | — | $49M |
| 2020 | $45M | $5M | 67.2% | 17.6% | — | — | $8M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $16M | -$2M | 60.9% | -9.4% | — | $25M | $27M |
| Dec '25 | $16M | -$1M | 0.0% | -2.8% | — | $25M | $24M |
| Sep '25 | $17M | -$2M | 0.0% | -9.0% | — | $25M | $25M |
| Jun '25 | $15M | -$4M | 0.0% | -19.2% | — | $25M | $20M |
| Mar '25 | $13M | -$4M | 63.5% | -25.3% | — | $25M | $21M |
| Dec '24 | $13M | $2M | 82.3% | 17.7% | — | $25M | $20M |
| Sep '24 | $15M | -$2M | 63.9% | -19.8% | — | $20M | $22M |
| Jun '24 | $15M | -$3M | 56.0% | -19.7% | — | $20M | $24M |
| Mar '24 | $13M | -$10M | 47.7% | -77.4% | — | $15M | $24M |
| Dec '23 | $15M | -$2M | 85.3% | -13.8% | -$17M | $15M | $27M |
| Sep '23 | $15M | $17M | 57.9% | 112.9% | $19M | $0 | $25M |
| Jun '23 | $17M | -$8M | 54.2% | -45.1% | $4M | $10M | $8M |
| Mar '23 | $12M | -$10M | 47.0% | -78.6% | -$6M | $23M | $17M |
| Dec '22 | $16M | -$11M | 51.5% | -62.8% | -$4M | $28M | $32M |
| Sep '22 | $16M | -$10M | 55.0% | -59.2% | -$7M | $20M | $35M |
| Jun '22 | $18M | -$8M | 58.1% | -39.2% | -$3M | $15M | $38M |
| Mar '22 | $21M | -$1M | 60.6% | -4.3% | -$19M | $15M | $41M |
| Dec '21 | $18M | -$22M | 45.6% | -51.7% | — | — | $49M |
| Sep '21 | $20M | -$11M | 43.1% | -64.5% | — | — | — |
| Jun '21 | $15M | -$12M | 51.0% | -90.0% | — | — | — |
How the market has priced DERM against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Journey Medical Corp's revenue has grown 6.6% per year. These are computed facts, not advice.
As of FY2025, Journey Medical Corp reported $25M of total debt against $24M of cash; operating income covered interest expense -2.2×.
In FY2025, gross margin was 65.8%, operating margin -13.3%, and net margin -18.7%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.